3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Solitary Fibrous Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Liver Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Granuloma, Plasma Cell
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Interventions
Temozolomide
162
Radiosurgery
115
Radiotherapy
100
Bevacizumab
96
Magnetic Resonance Spectroscopy
65
Carboplatin
48
Etoposide
34
pembrolizumab
33
Surgical Procedures, Operative
33
Irinotecan
33
Nivolumab
32
Cyclophosphamide
32
Erlotinib Hydrochloride
31
Radiation
30
Carmustine
28
Lomustine
25
Cisplatin
25
Trastuzumab
23
Ipilimumab
23
Filgrastim
23
Vincristine
20
Mental Status and Dementia Tests
20
Aminolevulinic Acid
19
Topotecan
18
Pemetrexed
18
Capecitabine
18
Specimen Handling
17
Sorafenib
15
Radiotherapy, Intensity-Modulated
15
Imatinib Mesylate
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Brain Neoplasms
×
repotrectinib
×
Clear all
NCT06315010
2026-02-25
REPOSE
MedSIR
Phase 2
Recruiting
20 enrolled